Trial | NCT01997203  Report issue

Title

Long Term Vitamin D Therapy in HCV Treated Patients
Effect of Long-term Vitamin D Therapy on IL-6, Visfatin and Hyaluronic Acid in Hepatitis C Virus Patients' Assessment

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    100
Treatment of hepatitis C virus (HCV) infection was carried out using pegylated interferon (PEG-IFN), ribavirin (RBV) and vitamin D (vit D) for 48 weeks in HCV genotypes 4a subjects. The purpose of this study is to determine the effect of vitamin D on liver affection in such patients.
Fifty patients study group administered vit D were compared with 50 patients control group without vit D. The results showed a significant elevation in vit D levels during the time period, and significant reduction on HCV RNA from the 12th wk to reach zero level in 24th wk. Interleukin 6 (IL-6), visfatin and hyaluronic acid levels were reduced significantly to reach normal values. These concentrations reduction by the effect of vit D on HCV indicated the reduction in inflammation, infection and liver cirrhosis and nearly amelioration HCV.
Study Started
Apr 30
2012
Primary Completion
Apr 30
2013
Study Completion
Apr 30
2013
Last Update
Nov 28
2013
Estimate

Drug Vitamin D

vitamin D was given to 50 patients (HCV under treatment)

  • Other names: pegylated interferon, ribavirin

HCV patients under treatment Experimental

Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D. Dose of vitamin D 15,000 IU/week

HCV without Vit D No Intervention

Criteria 

Inclusion Criteria:

Chronic HCV infection (positive HCV Ab more than 6 months)
Treated with pegylated interferon and ribavirin

Exclusion Criteria:

Coinfection with Hepatitis B or Hepatitis D or Human Immunodeficiency Virus
Previous non response to antiviral therapy.
Other causes of chronic liver diseases as schistosomiasis, Wilson disease and alcoholic liver disease.
No Results Posted